Bliuc D, Tran T, van Geel T, et al. - By prospectively following participants from the population-based Canadian Multicentre Osteoporosis Study between 1996 and 2011, researchers ascertained if the reduction in the rate of bone loss mediates the connection between bisphosphonates and mortality. Using linear regression, the rate of bone loss was calculated and annual information was acquired on the use of medication. Compared with no loss, rapid bone loss was linked to more than 2-fold higher mortality risk. According to mediation analysis, 39% of the nitrogen bisphosphonates (nBP; alendronate or risedronate) association with mortality was linked to a decline in the rate of bone loss. This finding offers an insight into the mechanism in osteoporotic patients between nBP and survival benefit.